BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 25204374)

  • 21. The effects of etoposide on testicular function in boys treated for Hodgkin's disease.
    Gerres L; Brämswig JH; Schlegel W; Jürgens H; Schellong G
    Cancer; 1998 Nov; 83(10):2217-22. PubMed ID: 9827728
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group.
    Schellong G; Pötter R; Brämswig J; Wagner W; Prott FJ; Dörffel W; Körholz D; Mann G; Rath B; Reiter A; Weissbach G; Riepenhausen M; Thiemann M; Schwarze EW
    J Clin Oncol; 1999 Dec; 17(12):3736-44. PubMed ID: 10577845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease.
    Brosteanu O; Hasenclever D; Loeffler M; Diehl V;
    Ann Hematol; 2004 Mar; 83(3):176-82. PubMed ID: 15064867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
    Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
    Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis.
    Skoetz N; Trelle S; Rancea M; Haverkamp H; Diehl V; Engert A; Borchmann P
    Lancet Oncol; 2013 Sep; 14(10):943-52. PubMed ID: 23948348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
    Eich HT; Diehl V; Görgen H; Pabst T; Markova J; Debus J; Ho A; Dörken B; Rank A; Grosu AL; Wiegel T; Karstens JH; Greil R; Willich N; Schmidberger H; Döhner H; Borchmann P; Müller-Hermelink HK; Müller RP; Engert A
    J Clin Oncol; 2010 Sep; 28(27):4199-206. PubMed ID: 20713848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of advanced stage Hodgkin lymphoma--it's all about risk-benefit.
    Phipps C; Lee YS; Hwang W
    Br J Haematol; 2012 Oct; 159(1):113-5. PubMed ID: 22823109
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.
    Shankar A; Hayward J; Kirkwood A; McCarthy K; Hewitt M; Morland B; Daw S
    Br J Haematol; 2014 May; 165(4):534-44. PubMed ID: 24754633
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
    Diehl V; Franklin J; Pfreundschuh M; Lathan B; Paulus U; Hasenclever D; Tesch H; Herrmann R; Dörken B; Müller-Hermelink HK; Dühmke E; Loeffler M;
    N Engl J Med; 2003 Jun; 348(24):2386-95. PubMed ID: 12802024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial.
    von Tresckow B; Plütschow A; Fuchs M; Klimm B; Markova J; Lohri A; Kral Z; Greil R; Topp MS; Meissner J; Zijlstra JM; Soekler M; Stein H; Eich HT; Mueller RP; Diehl V; Borchmann P; Engert A
    J Clin Oncol; 2012 Mar; 30(9):907-13. PubMed ID: 22271480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of advanced Hodgkin lymphoma].
    Kreissl S; Borchmann P
    Dtsch Med Wochenschr; 2013 Jun; 138(23):1212-4. PubMed ID: 23720173
    [No Abstract]   [Full Text] [Related]  

  • 32. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
    Engert A; Diehl V; Franklin J; Lohri A; Dörken B; Ludwig WD; Koch P; Hänel M; Pfreundschuh M; Wilhelm M; Trümper L; Aulitzky WE; Bentz M; Rummel M; Sezer O; Müller-Hermelink HK; Hasenclever D; Löffler M
    J Clin Oncol; 2009 Sep; 27(27):4548-54. PubMed ID: 19704068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
    Engert A; Schiller P; Josting A; Herrmann R; Koch P; Sieber M; Boissevain F; De Wit M; Mezger J; Duhmke E; Willich N; Muller RP; Schmidt BF; Renner H; Muller-Hermelink HK; Pfistner B; Wolf J; Hasenclever D; Loffler M; Diehl V;
    J Clin Oncol; 2003 Oct; 21(19):3601-8. PubMed ID: 12913100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized trial of CVPP for three versus six cycles in favorable-prognosis and CVPP versus AOPE plus radiotherapy in intermediate-prognosis untreated Hodgkin's disease.
    Pavlovsky S; Schvartzman E; Lastiri F; Magnasco H; Corrado C; Raslawski E; Cancela ME; Ardaiz MC; Cerutti I; Rosso A; Bruno S; Aranguren PN; Salvarezza A; Donato H; Dibar E; Zirone S
    J Clin Oncol; 1997 Jul; 15(7):2652-8. PubMed ID: 9215837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early intensification treatment approach in advanced-stage Hodgkin lymphoma.
    Borchmann P
    Hematol Oncol Clin North Am; 2014 Feb; 28(1):65-74. PubMed ID: 24287068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hodgkin disease in children: results of a prospective randomized trial in a single institution in Argentina.
    Sackmann-Muriel F; Zubizarreta P; Gallo G; Scopinaro M; Alderete D; Alfaro E; Casak S; Chantada G; Felice MS; Quinteros R
    Med Pediatr Oncol; 1997 Dec; 29(6):544-52. PubMed ID: 9324342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease.
    Loeffler M; Diehl V; Pfreundschuh M; Rühl U; Hasenclever D; Nisters-Backes H; Sieber M; Tesch H; Franklin J; Geilen W; Bartels H; Cartoni C; Dölken G; Enzian J; Fuchs R; Gassmann W; Gerhartz H; Hagen-Aukamp U; Hiller E; Hinkelbein H; Hinterberger W; Kirchner H; Koch P; Krüger B; Schwarze EW
    J Clin Oncol; 1997 Jun; 15(6):2275-87. PubMed ID: 9196141
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
    Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
    J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report.
    Bartlett NL; Rosenberg SA; Hoppe RT; Hancock SL; Horning SJ
    J Clin Oncol; 1995 May; 13(5):1080-8. PubMed ID: 7537796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.